Oakland, California – On April 17, 2016, over 900 people from around the world joined the Multidisciplinary Association for Psychedelic Studies to celebrate three decades of advancements in psychedelic research and therapy. The fundraising goal was to support the Phase 3 clinical trials, which are essential to making MDMA-assisted psychotherapy a legal prescription treatment for post-traumatic stress disorder.Continue Reading
New Science of Psychedelics
This blog discusses advances in the application of psychedelics (such as ayahuasca, LSD, MDMA and psilocybin) to medicine, mind research, and public policy—including the mainstreaming of psychedelic-assisted therapies for people dealing with addiction, depression, and PTSD. It tracks research breakthroughs reported by the Multidisciplinary Association of Psychedelic Studies (MAPS).